



tranScrip welcomes Senior Partner, Richard Vickers

7 June 2021

tranScrip is delighted to announce the appointment of Richard Vickers as a Senior Partner.

Richard brings nearly 20 years' experience in the pharmaceutical industry covering all stages of drug development from early preclinical research through to registrational clinical trials. Richard's primary area of focus is in infectious diseases but also works on multiple other therapeutic areas.

SENIOR PARTNER

Following post-doctoral studies and a stipendiary lectureship at Saint Catherine's College University of Oxford, Richard joined the spin-out company Summit Therapeutics progressing to CSO. During his time at Summit, Richard oversaw a portfolio of discovery and clinical stage projects. This included preclinical studies, clinical trial development and oversight, leading interactions with global regulatory bodies and managing KOL networks and scientific advisory boards. He was also actively involved in commercial strategy, launch planning and both in- and out-licensing and due diligence.

NEW APPOINTMENT

Although Richard's main therapeutic area of expertise is infectious diseases, Richard brings a wealth of expertise and experience in strategic oversight of all aspects of drug development across multiple therapeutic areas.

Flic Gabbay, tranScrip's Managing Partner said, "Richard brings an exciting range of CSO skills to tranScrip which continue to build the breadth and expertise in the teams we offer to support pharma companies in drug development, peri-registration and launch. In the growing demand for tranScrip, especially in infectious disease, we are thrilled to have another C-suite level partner to support our clients driving hard to ensure best possible chance of success for their projects."